<br>        Inclusion Criteria:<br><br>          -  Provision of signed and dated, written informed consent prior to any study specific<br>             procedures.<br><br>          -  Male and non-pregnant, non-lactating female patients aged 18 - 55 years with asthma<br>             and with suitable veins for cannulation or repeated venipuncture.<br><br>          -  Non-smoker or former smoker who quit = 6 months prior to Visit 1 and have a total<br>             smoking history of = 10 pack-years. Note: Pack-years are calculated by dividing the<br>             number of cigarettes smoked per day by 20 (the number of cigarettes in a pack) and<br>             multiplying this figure by the number of years a person has been smoking. For example,<br>             a person who smokes 40 cigarettes a day and has been smoking for 10 years would have a<br>             20 pack-year smoking history (40 cigarettes per day ÷ 20 cigarettes per pack = 2; 2 ×<br>             10 years of smoking = 20 pack-year history).<br><br>          -  Patient with documented clinical diagnosis of asthma for = 6 months before Visit 1<br>             according to Global Initiative for Asthma (GINA) guidelines.<br><br>          -  Patient with blood pressure (defined as systolic blood pressure [SBP] = 90 and = 140<br>             mmHg, and diastolic blood pressure [DBP] = 50 and = 90 mmHg) at Screening, measured<br>             after resting in the supine position for 5 minutes.<br><br>          -  Patient with no relevant clinical laboratory findings at Screening (Visits 1 or 2) as<br>             judged by the Investigator.<br><br>          -  Patient on stable dose of ICSs for at least 1 month prior to Visit 1. Patients on<br>             bronchodilators will need to do appropriate wash-out prior to the pulmonary function<br>             test at Visit 2.<br><br>          -  Patient with pre-bronchodilator forced expiratory volume in 1 second (FEV1) at Visit 2<br>             = 40% and = 90% of predicted (mean of 2 pre-bronchodilator measurements taken 30<br>             minutes apart).<br><br>          -  Patient who demonstrates the ability to use the study inhalation device properly.<br><br>        Patient able to perform acceptable pulmonary function testing for FEV1 according to<br>        American Thoracic Society (ATS)/European Respiratory Society (ERS) acceptability criteria.<br><br>          -  Negative pregnancy test (serum pregnancy test at Screening) for female patients.<br><br>               -  Female patients must be post-menopausal, surgically sterile, or must be able to<br>                  adhere to the conditions of contraceptive requirements. Male patients must be<br>                  surgically sterile or must be able to adhere to the conditions of contraceptive<br>                  requirements.<br><br>          -  Patients willing not to donate blood during the study and for 3 months following their<br>             last dose of IMP.<br><br>          -  Patient willing and able to follow study directions and restrictions.<br><br>          -  Patient must be able to read, speak and understand German language.<br><br>        Exclusion Criteria:<br><br>          -  Patient has known or suspected hypersensitivity to the IMP or excipients, including<br>             lactose (Note: lactose intolerance is not an exclusion criterion).<br><br>          -  Patient who has used systemic steroid in the 6 weeks before Visit 1.<br><br>          -  Patient with a history of hospitalization due to asthma in the 6 months prior to Visit<br>             1 or a history of intubation because of asthma at any time in their lifetime.<br><br>          -  Patient with any active pulmonary disease other than asthma.<br><br>          -  Patient non-compliant with study procedures in the Screening period (prior to<br>             randomization) -as judged by the Investigator.<br><br>          -  Patient under treatment with biologicals such as monoclonal antibodies or chimeric<br>             biomolecules including omalizumab, mepolizumab, and reslizumab within 6 months or 5<br>             half-lives before Visit 1, whichever is longer.<br><br>          -  Patient treated with any investigational drug within 30 days (or 5 half-lives,<br>             whichever is longer) prior to Visit 1.<br><br>          -  Patient on treatment with strong cytochrome P450 (CYP)3A4 inhibitors such as<br>             ketoconazole or itraconazole or CYP3A4 inducers such as rifampin at Visit 1 or within<br>             14 days prior to administration of IMP.<br><br>          -  Patient with a history, laboratory abnormality, or clinical suspicion of any<br>             clinically relevant disease or disorder, including uncontrolled hypertension or<br>             uncontrolled diabetes, which, in the opinion of the Investigator, may either put the<br>             patient at risk because of participation in the study, or influence the results or the<br>             patient's ability to participate in the study, or any other safety concerns in the<br>             opinion of the Investigator.<br><br>          -  Patient with diagnosis of any kind of chronic hepatitis or known human<br>             immunodeficiency virus (HIV) infections at the time of enrolment.<br><br>          -  Patient with any active malignancy or treatment thereof within the five years prior to<br>             enrolment.<br><br>          -  Patient with any clinically important abnormalities in rhythm, conduction, or<br>             morphology of the screening 12-lead ECG as judged by the Investigator on the screening<br>             ECG.<br><br>          -  Patient with prolonged QT interval using Fridericia's correction = 450 msec for males<br>             and females on the screening ECG or family history of long QT syndrome.<br><br>          -  Patient with PR (PQ) interval prolongation (> 240 msec), intermittent second or third<br>             degree atrio-ventricular (AV) block or AV dissociation or with QRS interval = 120 msec<br>             or any other ECG abnormality which might affect the evaluation of the central ECG<br>             reading on the screening ECG.<br><br>          -  Patient with heart rate (HR) < 45 beat per minute (bpm) or > 90 bpm at Screening ECG.<br><br>          -  Patient with implanted cardiac defibrillator and patients with sustained symptomatic<br>             ventricular and/or atrial tachyarrhythmia.<br><br>          -  Patient with any contraindication against the use of sympathomimetic drugs as judged<br>             by the Investigator.<br><br>          -  Patient with unstable angina pectoris or stable angina pectoris classified higher than<br>             Canadian Cardiovascular Society Class II, or a myocardial infarction, or stroke within<br>             6 months before Visit 1.<br><br>          -  Patient with a history of hospitalization within 12 months caused by heart failure or<br>             a diagnosis of heart failure higher than New York Heart Association (NYHA) Class II.<br><br>          -  Patient who failed the screening procedures or patient with previous participation in<br>             the current study. Patients who failed the screening procedures may be re-screened<br>             once only.<br><br>          -  Patient with a history of or current alcohol or drug abuse (including marijuana), as<br>             judged by the Investigator.<br><br>          -  Patient with planned in-patient surgery, major dental procedure or hospitalization<br>             during the study.<br><br>          -  Patient involved in the planning and/or conduct of the study (applies to both<br>             AstraZeneca staff, contract research organization (CRO) staff and/or staff at the<br>             study site).<br><br>          -  Vulnerable person (e.g., per;<br>        Inclusion Criteria:<br><br>          -  Provision of signed and dated, written informed consent prior to any study specific<br>             procedures.<br><br>          -  Male and non-pregnant, non-lactating female patients aged 18 - 55 years with asthma<br>             and with suitable veins for cannulation or repeated venipuncture.<br><br>          -  Non-smoker or former smoker who quit = 6 months prior to Visit 1 and have a total<br>             smoking history of = 10 pack-years. Note: Pack-years are calculated by dividing the<br>             number of cigarettes smoked per day by 20 (the number of cigarettes in a pack) and<br>             multiplying this figure by the number of years a person has been smoking. For example,<br>             a person who smokes 40 cigarettes a day and has been smoking for 10 years would have a<br>             20 pack-year smoking history (40 cigarettes per day ÷ 20 cigarettes per pack = 2; 2 ×<br>             10 years of smoking = 20 pack-year history).<br><br>          -  Patient with documented clinical diagnosis of asthma for = 6 months before Visit 1<br>             according to Global Initiative for Asthma (GINA) guidelines.<br><br>          -  Patient with blood pressure (defined as systolic blood pressure [SBP] = 90 and = 140<br>             mmHg, and diastolic blood pressure [DBP] = 50 and = 90 mmHg) at Screening, measured<br>             after resting in the supine position for 5 minutes.<br><br>          -  Patient with no relevant clinical laboratory findings at Screening (Visits 1 or 2) as<br>             judged by the Investigator.<br><br>          -  Patient on stable dose of ICSs for at least 1 month prior to Visit 1. Patients on<br>             bronchodilators will need to do appropriate wash-out prior to the pulmonary function<br>             test at Visit 2.<br><br>          -  Patient with pre-bronchodilator forced expiratory volume in 1 second (FEV1) at Visit 2<br>             = 40% and = 90% of predicted (mean of 2 pre-bronchodilator measurements taken 30<br>             minutes apart).<br><br>          -  Patient who demonstrates the ability to use the study inhalation device properly.<br><br>        Patient able to perform acceptable pulmonary function testing for FEV1 according to<br>        American Thoracic Society (ATS)/European Respiratory Society (ERS) acceptability criteria.<br><br>          -  Negative pregnancy test (serum pregnancy test at Screening) for female patients.<br><br>               -  Female patients must be post-menopausal, surgically sterile, or must be able to<br>                  adhere to the conditions of contraceptive requirements. Male patients must be<br>                  surgically sterile or must be able to adhere to the conditions of contraceptive<br>                  requirements.<br><br>          -  Patients willing not to donate blood during the study and for 3 months following their<br>             last dose of IMP.<br><br>          -  Patient willing and able to follow study directions and restrictions.<br><br>          -  Patient must be able to read, speak and understand German language.<br><br>        Exclusion Criteria:<br><br>          -  Patient has known or suspected hypersensitivity to the IMP or excipients, including<br>             lactose (Note: lactose intolerance is not an exclusion criterion).<br><br>          -  Patient who has used systemic steroid in the 6 weeks before Visit 1.<br><br>          -  Patient with a history of hospitalization due to asthma in the 6 months prior to Visit<br>             1 or a history of intubation because of asthma at any time in their lifetime.<br><br>          -  Patient with any active pulmonary disease other than asthma.<br><br>          -  Patient non-compliant with study procedures in the Screening period (prior to<br>             randomization) -as judged by the Investigator.<br><br>          -  Patient under treatment with biologicals such as monoclonal antibodies or chimeric<br>             biomolecules including omalizumab, mepolizumab, and reslizumab within 6 months or 5<br>             half-lives before Visit 1, whichever is longer.<br><br>          -  Patient treated with any investigational drug within 30 days (or 5 half-lives,<br>             whichever is longer) prior to Visit 1.<br><br>          -  Patient on treatment with strong cytochrome P450 (CYP)3A4 inhibitors such as<br>             ketoconazole or itraconazole or CYP3A4 inducers such as rifampin at Visit 1 or within<br>             14 days prior to administration of IMP.<br><br>          -  Patient with a history, laboratory abnormality, or clinical suspicion of any<br>             clinically relevant disease or disorder, including uncontrolled hypertension or<br>             uncontrolled diabetes, which, in the opinion of the Investigator, may either put the<br>             patient at risk because of participation in the study, or influence the results or the<br>             patient's ability to participate in the study, or any other safety concerns in the<br>             opinion of the Investigator.<br><br>          -  Patient with diagnosis of any kind of chronic hepatitis or known human<br>             immunodeficiency virus (HIV) infections at the time of enrolment.<br><br>          -  Patient with any active malignancy or treatment thereof within the five years prior to<br>             enrolment.<br><br>          -  Patient with any clinically important abnormalities in rhythm, conduction, or<br>             morphology of the screening 12-lead ECG as judged by the Investigator on the screening<br>             ECG.<br><br>          -  Patient with prolonged QT interval using Fridericia's correction = 450 msec for males<br>             and females on the screening ECG or family history of long QT syndrome.<br><br>          -  Patient with PR (PQ) interval prolongation (> 240 msec), intermittent second or third<br>             degree atrio-ventricular (AV) block or AV dissociation or with QRS interval = 120 msec<br>             or any other ECG abnormality which might affect the evaluation of the central ECG<br>             reading on the screening ECG.<br><br>          -  Patient with heart rate (HR) < 45 beat per minute (bpm) or > 90 bpm at Screening ECG.<br><br>          -  Patient with implanted cardiac defibrillator and patients with sustained symptomatic<br>             ventricular and/or atrial tachyarrhythmia.<br><br>          -  Patient with any contraindication against the use of sympathomimetic drugs as judged<br>             by the Investigator.<br><br>          -  Patient with unstable angina pectoris or stable angina pectoris classified higher than<br>             Canadian Cardiovascular Society Class II, or a myocardial infarction, or stroke within<br>             6 months before Visit 1.<br><br>          -  Patient with a history of hospitalization within 12 months caused by heart failure or<br>             a diagnosis of heart failure higher than New York Heart Association (NYHA) Class II.<br><br>          -  Patient who failed the screening procedures or patient with previous participation in<br>             the current study. Patients who failed the screening procedures may be re-screened<br>             once only.<br><br>          -  Patient with a history of or current alcohol or drug abuse (including marijuana), as<br>             judged by the Investigator.<br><br>          -  Patient with planned in-patient surgery, major dental procedure or hospitalization<br>             during the study.<br><br>          -  Patient involved in the planning and/or conduct of the study (applies to both<br>             AstraZeneca staff, contract research organization (CRO) staff and/or staff at the<br>             study site).<br><br>          -  Vulnerable person (e.g., per;<br>        Inclusion Criteria:<br><br>          -  Provision of signed and dated, written informed consent prior to any study specific<br>             procedures.<br><br>          -  Male and non-pregnant, non-lactating female patients aged 18 - 55 years with asthma<br>             and with suitable veins for cannulation or repeated venipuncture.<br><br>          -  Non-smoker or former smoker who quit = 6 months prior to Visit 1 and have a total<br>             smoking history of = 10 pack-years. Note: Pack-years are calculated by dividing the<br>             number of cigarettes smoked per day by 20 (the number of cigarettes in a pack) and<br>             multiplying this figure by the number of years a person has been smoking. For example,<br>             a person who smokes 40 cigarettes a day and has been smoking for 10 years would have a<br>             20 pack-year smoking history (40 cigarettes per day ÷ 20 cigarettes per pack = 2; 2 ×<br>             10 years of smoking = 20 pack-year history).<br><br>          -  Patient with documented clinical diagnosis of asthma for = 6 months before Visit 1<br>             according to Global Initiative for Asthma (GINA) guidelines.<br><br>          -  Patient with blood pressure (defined as systolic blood pressure [SBP] = 90 and = 140<br>             mmHg, and diastolic blood pressure [DBP] = 50 and = 90 mmHg) at Screening, measured<br>             after resting in the supine position for 5 minutes.<br><br>          -  Patient with no relevant clinical laboratory findings at Screening (Visits 1 or 2) as<br>             judged by the Investigator.<br><br>          -  Patient on stable dose of ICSs for at least 1 month prior to Visit 1. Patients on<br>             bronchodilators will need to do appropriate wash-out prior to the pulmonary function<br>             test at Visit 2.<br><br>          -  Patient with pre-bronchodilator forced expiratory volume in 1 second (FEV1) at Visit 2<br>             = 40% and = 90% of predicted (mean of 2 pre-bronchodilator measurements taken 30<br>             minutes apart).<br><br>          -  Patient who demonstrates the ability to use the study inhalation device properly.<br><br>        Patient able to perform acceptable pulmonary function testing for FEV1 according to<br>        American Thoracic Society (ATS)/European Respiratory Society (ERS) acceptability criteria.<br><br>          -  Negative pregnancy test (serum pregnancy test at Screening) for female patients.<br><br>               -  Female patients must be post-menopausal, surgically sterile, or must be able to<br>                  adhere to the conditions of contraceptive requirements. Male patients must be<br>                  surgically sterile or must be able to adhere to the conditions of contraceptive<br>                  requirements.<br><br>          -  Patients willing not to donate blood during the study and for 3 months following their<br>             last dose of IMP.<br><br>          -  Patient willing and able to follow study directions and restrictions.<br><br>          -  Patient must be able to read, speak and understand German language.<br><br>        Exclusion Criteria:<br><br>          -  Patient has known or suspected hypersensitivity to the IMP or excipients, including<br>             lactose (Note: lactose intolerance is not an exclusion criterion).<br><br>          -  Patient who has used systemic steroid in the 6 weeks before Visit 1.<br><br>          -  Patient with a history of hospitalization due to asthma in the 6 months prior to Visit<br>             1 or a history of intubation because of asthma at any time in their lifetime.<br><br>          -  Patient with any active pulmonary disease other than asthma.<br><br>          -  Patient non-compliant with study procedures in the Screening period (prior to<br>             randomization) -as judged by the Investigator.<br><br>          -  Patient under treatment with biologicals such as monoclonal antibodies or chimeric<br>             biomolecules including omalizumab, mepolizumab, and reslizumab within 6 months or 5<br>             half-lives before Visit 1, whichever is longer.<br><br>          -  Patient treated with any investigational drug within 30 days (or 5 half-lives,<br>             whichever is longer) prior to Visit 1.<br><br>          -  Patient on treatment with strong cytochrome P450 (CYP)3A4 inhibitors such as<br>             ketoconazole or itraconazole or CYP3A4 inducers such as rifampin at Visit 1 or within<br>             14 days prior to administration of IMP.<br><br>          -  Patient with a history, laboratory abnormality, or clinical suspicion of any<br>             clinically relevant disease or disorder, including uncontrolled hypertension or<br>             uncontrolled diabetes, which, in the opinion of the Investigator, may either put the<br>             patient at risk because of participation in the study, or influence the results or the<br>             patient's ability to participate in the study, or any other safety concerns in the<br>             opinion of the Investigator.<br><br>          -  Patient with diagnosis of any kind of chronic hepatitis or known human<br>             immunodeficiency virus (HIV) infections at the time of enrolment.<br><br>          -  Patient with any active malignancy or treatment thereof within the five years prior to<br>             enrolment.<br><br>          -  Patient with any clinically important abnormalities in rhythm, conduction, or<br>             morphology of the screening 12-lead ECG as judged by the Investigator on the screening<br>             ECG.<br><br>          -  Patient with prolonged QT interval using Fridericia's correction = 450 msec for males<br>             and females on the screening ECG or family history of long QT syndrome.<br><br>          -  Patient with PR (PQ) interval prolongation (> 240 msec), intermittent second or third<br>             degree atrio-ventricular (AV) block or AV dissociation or with QRS interval = 120 msec<br>             or any other ECG abnormality which might affect the evaluation of the central ECG<br>             reading on the screening ECG.<br><br>          -  Patient with heart rate (HR) < 45 beat per minute (bpm) or > 90 bpm at Screening ECG.<br><br>          -  Patient with implanted cardiac defibrillator and patients with sustained symptomatic<br>             ventricular and/or atrial tachyarrhythmia.<br><br>          -  Patient with any contraindication against the use of sympathomimetic drugs as judged<br>             by the Investigator.<br><br>          -  Patient with unstable angina pectoris or stable angina pectoris classified higher than<br>             Canadian Cardiovascular Society Class II, or a myocardial infarction, or stroke within<br>             6 months before Visit 1.<br><br>          -  Patient with a history of hospitalization within 12 months caused by heart failure or<br>             a diagnosis of heart failure higher than New York Heart Association (NYHA) Class II.<br><br>          -  Patient who failed the screening procedures or patient with previous participation in<br>             the current study. Patients who failed the screening procedures may be re-screened<br>             once only.<br><br>          -  Patient with a history of or current alcohol or drug abuse (including marijuana), as<br>             judged by the Investigator.<br><br>          -  Patient with planned in-patient surgery, major dental procedure or hospitalization<br>             during the study.<br><br>          -  Patient involved in the planning and/or conduct of the study (applies to both<br>             AstraZeneca staff, contract research organization (CRO) staff and/or staff at the<br>             study site).<br><br>          -  Vulnerable person (e.g., per;<br>        Inclusion Criteria:<br><br>          -  Provision of signed and dated, written informed consent prior to any study specific<br>             procedures.<br><br>          -  Male and non-pregnant, non-lactating female patients aged 18 - 55 years with asthma<br>             and with suitable veins for cannulation or repeated venipuncture.<br><br>          -  Non-smoker or former smoker who quit = 6 months prior to Visit 1 and have a total<br>             smoking history of = 10 pack-years. Note: Pack-years are calculated by dividing the<br>             number of cigarettes smoked per day by 20 (the number of cigarettes in a pack) and<br>             multiplying this figure by the number of years a person has been smoking. For example,<br>             a person who smokes 40 cigarettes a day and has been smoking for 10 years would have a<br>             20 pack-year smoking history (40 cigarettes per day ÷ 20 cigarettes per pack = 2; 2 ×<br>             10 years of smoking = 20 pack-year history).<br><br>          -  Patient with documented clinical diagnosis of asthma for = 6 months before Visit 1<br>             according to Global Initiative for Asthma (GINA) guidelines.<br><br>          -  Patient with blood pressure (defined as systolic blood pressure [SBP] = 90 and = 140<br>             mmHg, and diastolic blood pressure [DBP] = 50 and = 90 mmHg) at Screening, measured<br>             after resting in the supine position for 5 minutes.<br><br>          -  Patient with no relevant clinical laboratory findings at Screening (Visits 1 or 2) as<br>             judged by the Investigator.<br><br>          -  Patient on stable dose of ICSs for at least 1 month prior to Visit 1. Patients on<br>             bronchodilators will need to do appropriate wash-out prior to the pulmonary function<br>             test at Visit 2.<br><br>          -  Patient with pre-bronchodilator forced expiratory volume in 1 second (FEV1) at Visit 2<br>             = 40% and = 90% of predicted (mean of 2 pre-bronchodilator measurements taken 30<br>             minutes apart).<br><br>          -  Patient who demonstrates the ability to use the study inhalation device properly.<br><br>        Patient able to perform acceptable pulmonary function testing for FEV1 according to<br>        American Thoracic Society (ATS)/European Respiratory Society (ERS) acceptability criteria.<br><br>          -  Negative pregnancy test (serum pregnancy test at Screening) for female patients.<br><br>               -  Female patients must be post-menopausal, surgically sterile, or must be able to<br>                  adhere to the conditions of contraceptive requirements. Male patients must be<br>                  surgically sterile or must be able to adhere to the conditions of contraceptive<br>                  requirements.<br><br>          -  Patients willing not to donate blood during the study and for 3 months following their<br>             last dose of IMP.<br><br>          -  Patient willing and able to follow study directions and restrictions.<br><br>          -  Patient must be able to read, speak and understand German language.<br><br>        Exclusion Criteria:<br><br>          -  Patient has known or suspected hypersensitivity to the IMP or excipients, including<br>             lactose (Note: lactose intolerance is not an exclusion criterion).<br><br>          -  Patient who has used systemic steroid in the 6 weeks before Visit 1.<br><br>          -  Patient with a history of hospitalization due to asthma in the 6 months prior to Visit<br>             1 or a history of intubation because of asthma at any time in their lifetime.<br><br>          -  Patient with any active pulmonary disease other than asthma.<br><br>          -  Patient non-compliant with study procedures in the Screening period (prior to<br>             randomization) -as judged by the Investigator.<br><br>          -  Patient under treatment with biologicals such as monoclonal antibodies or chimeric<br>             biomolecules including omalizumab, mepolizumab, and reslizumab within 6 months or 5<br>             half-lives before Visit 1, whichever is longer.<br><br>          -  Patient treated with any investigational drug within 30 days (or 5 half-lives,<br>             whichever is longer) prior to Visit 1.<br><br>          -  Patient on treatment with strong cytochrome P450 (CYP)3A4 inhibitors such as<br>             ketoconazole or itraconazole or CYP3A4 inducers such as rifampin at Visit 1 or within<br>             14 days prior to administration of IMP.<br><br>          -  Patient with a history, laboratory abnormality, or clinical suspicion of any<br>             clinically relevant disease or disorder, including uncontrolled hypertension or<br>             uncontrolled diabetes, which, in the opinion of the Investigator, may either put the<br>             patient at risk because of participation in the study, or influence the results or the<br>             patient's ability to participate in the study, or any other safety concerns in the<br>             opinion of the Investigator.<br><br>          -  Patient with diagnosis of any kind of chronic hepatitis or known human<br>             immunodeficiency virus (HIV) infections at the time of enrolment.<br><br>          -  Patient with any active malignancy or treatment thereof within the five years prior to<br>             enrolment.<br><br>          -  Patient with any clinically important abnormalities in rhythm, conduction, or<br>             morphology of the screening 12-lead ECG as judged by the Investigator on the screening<br>             ECG.<br><br>          -  Patient with prolonged QT interval using Fridericia's correction = 450 msec for males<br>             and females on the screening ECG or family history of long QT syndrome.<br><br>          -  Patient with PR (PQ) interval prolongation (> 240 msec), intermittent second or third<br>             degree atrio-ventricular (AV) block or AV dissociation or with QRS interval = 120 msec<br>             or any other ECG abnormality which might affect the evaluation of the central ECG<br>             reading on the screening ECG.<br><br>          -  Patient with heart rate (HR) < 45 beat per minute (bpm) or > 90 bpm at Screening ECG.<br><br>          -  Patient with implanted cardiac defibrillator and patients with sustained symptomatic<br>             ventricular and/or atrial tachyarrhythmia.<br><br>          -  Patient with any contraindication against the use of sympathomimetic drugs as judged<br>             by the Investigator.<br><br>          -  Patient with unstable angina pectoris or stable angina pectoris classified higher than<br>             Canadian Cardiovascular Society Class II, or a myocardial infarction, or stroke within<br>             6 months before Visit 1.<br><br>          -  Patient with a history of hospitalization within 12 months caused by heart failure or<br>             a diagnosis of heart failure higher than New York Heart Association (NYHA) Class II.<br><br>          -  Patient who failed the screening procedures or patient with previous participation in<br>             the current study. Patients who failed the screening procedures may be re-screened<br>             once only.<br><br>          -  Patient with a history of or current alcohol or drug abuse (including marijuana), as<br>             judged by the Investigator.<br><br>          -  Patient with planned in-patient surgery, major dental procedure or hospitalization<br>             during the study.<br><br>          -  Patient involved in the planning and/or conduct of the study (applies to both<br>             AstraZeneca staff, contract research organization (CRO) staff and/or staff at the<br>             study site).<br><br>          -  Vulnerable person (e.g., per